Identification of a Collagen Marker in Urine Improves the Detection of Colorectal Liver Metastases.,Journal of Proteome Research - X-MOL
Relationship between peripheral and mesenteric serum levels of CEA and CA 242 with staging and histopathological variables in colorectal adenocarcinoma
Comparison of two immunoassays for CA19-9, CEA and AFP tumor markers - Biochemia Medica
Whiteboard marker W-500 - 12 pieces - Apledox Brand Market
Evaluation of tumor markers for the differential diagnosis of benign and malignant ascites
Determination of carcinoembryonic antigen levels in peripheral and draining venous blood in patients with colorectal carcinoma
Key words with ''gastric cancer and tumor marker'' and number of... | Download Table
Prognostic and predictive value of CEA and CYFRA 21-1 levels in advanced non-small cell lung cancer patients treated with gefitinib or erlotinib
Gene Variants That Affect Levels of Circulating Tumor Markers Increase Identification of Patients With Pancreatic Cancer - Clinical Gastroenterology and Hepatology
Clinical utility of tumour marker velocity of cancer antigen 15–3 (CA 15–3) and carcinoembryonic antigen (CEA) in breast cancer surveillance - ScienceDirect
Pin on Nursing
Tumor Markers CEA, CA19-9 and CA125in Monitoring of Response to Systemic Chemotherapy in Patients with Advanced Gastric Cancer
Polydopamine nanosphere@silver nanoclusters for fluorescence detection of multiplex tumor markers - Nanoscale (RSC Publishing)
Tumor markers - Cusabio
KR101262202B1 - Predictive markers for ovarian cancer - Google Patents
Elevation of serum CEA and CA15‑3 levels during antitumor therapy predicts poor therapeutic response in advanced breast cancer patients
Comparison between CEA, CA 19-9 and CA 72-4 in Patients with Colon Cancer
Авицена Лабораторија
Cancers | Free Full-Text | Serum Tumor Markers in Pancreatic Cancer—Recent Discoveries | HTML
Clinical Value of Serum CEA, CA 19-9, CA 242 and AFP in Diagnosis of Gastrointestinal Tract Cancers - SciAlert Responsive Version
Tumor-Associated Trypsin Inhibitor (Tati) in Patients with Colorectal Carcinoma. A Critical Comparison with Cea
